In the wake of funding cuts to mRNA vaccine research, we revisit a February story about a promising vaccine for pancreatic cancer.

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in a UCLA clinical trial.

The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

The vaccine doesn't prevent cancer from happening in the first place, but an early-phase trial found it could reduce the odds of recurrence.

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

If you experience a loss of appetite or feel full after eating very little, this also may be a sign of pancreatic cancer. “The pancreas is nestled right near the first part of the small intestine, and tumors can cause food to back up or not get through to the small intestine as quickly,” said Dr. Reiss.

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small UCLA clinical trial suggests.

”Chronic, high alcohol use damages acinar cells in the pancreas, [which are] specialised cells that produce digestive enzymes,” Dr Mehra and colleagues say, explaining that the impact, in turn, increases inflammation and exacerbates damage to the pancreas.